Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.
Aged ≥18 years
Diagnosis of pathologically confirmed EG adenocarcinoma
Diagnosis of metastatic or recurrent disease
ECOG performance status of 0-1
Pregnant or lactating
HIV, active hepatitis C virus, or active hepatitis B virus infection, as determined by quantitative PCR (patients who have undergone negative testing prior to leukapheresis do not require repeat testing)
Receiving therapy for concurrent active malignancy
Note: Patients receiving treatment for in situ skin malignancies are not excluded.
Memorial Sloan Kettering Cancer Center
Lead sponsor